Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on STEM Times Arkansas.
Press releases published on August 8, 2025
XORTX Completes USD $114,500 Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Aug. 08, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late- …
Intermap Announces Date for Second Quarter Earnings
DENVER, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in 3D geospatial products and intelligence solutions, today announced that it plans to release second quarter 2025 …
Enovix Shareholder Second Reminder: Early Warrant Expiration Price Condition
FREMONT, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Enovix Corporation (Nasdaq: ENVX, ENVXW) (“Company” or “Enovix”), a leader in advanced silicon battery technology, today announced that the price of its common stock has exceeded $10.50 for fourteen …
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it has entered into a securities purchase agreement with …
Constellation Software Inc. Announces Results for the Second Quarter Ended June 30, 2025 and Declares Quarterly Dividend
TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the second quarter ended June 30, 2025 and declared a $1.00 per share dividend payable on October …
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee …
ChatAndBuild Debuts Worldwide, Powering AI App Creation in 40+ Languages as Industry M&A Heats Up
Photo Courtesy of: ChatAndBuild LONDON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- ChatAndBuild, the AI-powered platform that turns simple ideas into real, production-ready applications - directly from your phone or laptop - is now publicly available worldwide. …
Prize AI Technologies Launches $PRIZE Token Presale, Raises $100K+ Targeting $400B Arcade & Casino Market
Prize AI Technologies launched a $PRIZE token presale, raising $100K+ in the first week and targeting the $400B arcade/casino market. The platform integrates AI analytics with blockchain rewards through a consumer app and an operator dashboard. Stage 1 …
Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results
TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and …
Jeff Harsh named new Chief Operating Officer of Advantage Solutions Branded Services business segment
ST. LOUIS, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Advantage Solutions Inc (NASDAQ: ADV), announced the appointment of Jeff Harsh as the new Chief Operating Officer of its Branded Services business segment, effective Aug. 25. Harsh will join the company’s …
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today …
Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55 membrane expression; IND …
Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update
Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for Research in Vision and Ophthalmology Annual Meeting and …
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – Vepdegestrant is the first PROteolysis TArgeting Chimera ( …
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates
FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatment Significant regulatory and pipeline advancements achieved …
Commerce to Present at Upcoming Investor Conference
AUSTIN, Texas, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Commerce.com, Inc. (Nasdaq: CMRC) (formerly BigCommerce Holdings, Inc.), a provider of an open, intelligent ecosystem of technology solutions that empower businesses to unlock data potential and deliver …
Phunware Reports Second Quarter 2025 Financial Results
Delivers Strong First Half with Key Product Milestones and Customer Momentum Strong Liquidity Powering New Technology Improvements, AI Integration and Corporate Initiatives AUSTIN, Texas, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Phunware, Inc. (“Phunware” or the …
Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025
NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hyperion Defi, Inc. (NASDAQ: HYPD), the first U.S. public company to build a strategic treasury around the HYPE token and a pioneer in integrating decentralized finance with traditional corporate treasury …
NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard
TORONTO and HAIFA, Israel, Aug. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced that an independent study showed that exosomes produced by NurExone outperformed a …
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an …